Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non–muscle-invasive bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 35, Issue 5, 2017, Pages 201-207

  Steinberg, Ryan L ^a   Brooks, Nathan A ^a   Thomas, Lewis J ^a   Mott, Sarah L ^b   O'Donnell, Michael A ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Adjuvant immunologic; BCG Connaught; BCG vaccine; Mycobacterium bovis; Urinary bladder neoplasms

Indexed keywords

BCG VACCINE; RECOMBINANT ALPHA2B INTERFERON; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BCG CONNAUGHT; RECOMBINANT PROTEIN;

AGED; ARTICLE; BACTERIAL STRAIN; BLADDER BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; CONTROLLED STUDY; DISEASE DURATION; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYCOBACTERIUM BOVIS BCG; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TRANSURETHRAL RESECTION; TUMOR BIOPSY; BLADDER TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; INTRAVESICAL DRUG ADMINISTRATION; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RETREATMENT; TIME FACTOR; TREATMENT FAILURE; TUMOR INVASION; TUMOR RECURRENCE; TUMOR VOLUME;

ADMINISTRATION, INTRAVESICAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; CARCINOMA IN SITU; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; INTERFERON-ALPHA; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; RECOMBINANT PROTEINS; RETREATMENT; TIME FACTORS; TREATMENT FAILURE; TUMOR BURDEN; URINARY BLADDER NEOPLASMS;

EID: 85009343255     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2016.11.016     Document Type: Article

References (26)

1. [1] Morales, A., Eidinger, D., Bruce, A.W., Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116 (1976), 180–183.
2. [2] Lamm, D., Thor, D., Stogdill, V., Radwin, H., Bladder cancer immunotherapy. J Urol 128 (1982), 931–935.
3. [3] Shelley, M.D., Kynaston, H., Court, J., Wilt, T.J., Coles, B., Burgon, K., et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88 (2001), 209–216.
4. [4] Brosman, S.A., Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 128 (1982), 27–30.
5. [5] Lamm, D.L., Blumenstein, B.A., Crawford, E.D., Montie, J.E., Scardino, P., Grossman, H.B., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325 (1991), 1205–1209.
6. [6] Malmstrom, P.U., Wijkstrom, H., Lundholm, C., Wester, K., Busch, C., Norlen, B.J., 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161 (1999), 1124–1127.
7. [7] Malmstrom, P.U., Sylvester, R.J., Crawford, D.E., Friedrich, M., Krege, S., Rintala, E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 56 (2009), 247–256.
8. [8] Duchek, M., Johansson, R., Jahnson, S., Mestad, O., Hellstrom, P., Hellsten, S., et al. Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol 57 (2010), 25–31.
9. [9] Sylvester, R.J., Brausi, M.A., Kirkels, W.J., Hoeltl, W., Calais Da Silva, F., Powell, P.H., et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57 (2010), 766–773.
10. [10] Lamm, D.L., Blumenstein, B.A., David Crawford, E., Crissman, J.D., Lowe, B.A., Smith, J.A. Jr., et al. Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol 1 (1995), 119–126.
11. [11] Sylvester, R.J., van der, M.A., Lamm, D.L., Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002), 1964–1970.
12. [12] Sylvester, R.J., van der Meijden, A.P., Witjes, J.A., Kurth, K., Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174 (2005), 86–91 [discussion 2].
13. [13] Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. American Urological Association (AUA) Guidelines; 2016.
14. [14] Babjuk, M., Burger, M., Zigeuner, R., Shariat, S.F., van Rhijn, B.W., Comperat, E., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64 (2013), 639–653.
15. [15] Gan, C., Mostafid, H., Khan, M.S., Lewis, D.J., BCG immunotherapy for bladder cancer—the effects of substrain differences. Nat Rev Urol 10 (2013), 580–588.
16. [16] Rentsch, C.A., Birkhauser, F.D., Biot, C., Gsponer, J.R., Bisiaux, A., Wetterauer, C., et al. Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol 66 (2014), 677–688.
17. [17] Joudi, F.N., Smith, B.J., OʼDonnell, M.A., National BCGIPIG. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24 (2006), 344–348.
18. [18] Noon, A.P., Kulkarni, G.S., All bacillus Calmette-Guerin (BCG) strains are equal, but some BCG strains are more equal than others. Eur Urol 66 (2014), 689–691.
19. [19] Sengiku, A., Ito, M., Miyazaki, Y., Sawazaki, H., Takahashi, T., Ogura, K., A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J Urol 190 (2013), 50–54.
20. [20] Witjes, J.A., vd Meijden, A.P., Witjes, W.P., Doesburg, W., Schaafsma, H.E., Debruyne, F.M., A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. Eur J Cancer 29A (1993), 1672–1676.
21. [21] Witjes, W.P., Witjes, J.A., Oosterhof, G.O., Debruyne, M.J., Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guerin-Tice versus bacillus Calmette-Guerin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Semin Urol Oncol 14:1 Suppl. 1 (1996), S10–S16.
22. [22] Mostafid, A.H., Palou Redorta, J., Sylvester, R., Witjes, J.A., Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guerin. Eur Urol 67 (2015), 359–360.
23. [23] Nepple, K.G., Lightfoot, A.J., Rosevear, H.M., OʼDonnell, M.A., Lamm, D.L., Bladder Cancer Genitourinary Oncology Study G. Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol 184 (2010), 1915–1919.
24. [24] Luo, Y., Chen, X., Downs, T.M., DeWolf, W.C., OʼDonnell, M.A., IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol 162:4 (1999), 2399–2405.
25. [25] Catalona, W.J., Hudson, M.A., Gillen, D.P., Andriole, G.L., Ratliff, T.L., Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 137:2 (1987), 220–224.
26. [26] O'Donnell, M.A., Boehle, A., Treatment options for BCG failures. World J Urol 24:5 (2006), 481–487.